Business
Kincell Bio Announces Strategic Collaboration with Major Academic Medical Center to Advance Cell and Gene Therapy Innovation
DURHAM, N.C., October 06, 2025--Kincell Bio Inc., a cell therapy contract development and manufacturing organization, today announced the signing of a memorandum of understanding with the Duke University School of Medicine. The collaboration is designed to accelerate innovation in cell and gene therapy research, strengthen translational pathways, and support the development of scalable and efficient manufacturing solutions for advanced biologics.
About this update from Duke Energy Corporation (holding Company)
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":3063,"height":1100,"url":"https://media.zenfs.com/en/business-wire.com/e6ee417a547fff3a40b1034a7e1e975e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1kZ5M8WXNRXW_1XjWRsbMA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM0NTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/e6ee417a547fff3a40b1034a7e1e975e","width":960,"height":345},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/ZUlPr.s5xmWHEiRMKVFSRw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTIzMDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/e6ee417a547fff3a40b1034a7e1e975e","width":640,"height":230},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/B3YaRgt7L_QZViz36ZF8Sw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04NjI7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/e6ee417a547fff3a40b1034a7e1e975e","width":1200,"height":431}},"lazy":false},{"type":"text","content":"DURHAM, N.C., October 06, 2025--(BUSINESS WIRE)--Kincell Bio Inc., a cell therapy contract development and manufacturing organization, today announced the signing of a memorandum of understanding with the Duke University School of Medicine. The collaboration is designed to accelerate innovation in cell and gene therapy research, strengthen translational pathways, and support the development of scalable and efficient manufacturing solutions for advanced biologics.","length":467,"tagName":"p"},{"type":"text","content":"Under the agreement, Kincell Bio and Duke will jointly pursue opportunities to align academic discovery with industrial expertise. The partnership will be guided by a joint steering committee, co-chaired by Bruce Thompson, Ph.D., chief technology officer at Kincell Bio, and Beth Shaz, M.D., deputy director of the Marcus Center for Cellular Cures (MC3) and Professor of Pathology at Duke.","length":389,"tagName":"p"},{"type":"text","content":"The committee will oversee initiatives that include:","length":52,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Program referral and cross-support between Kincell Bio and MC3, enabling seamless coordination of clinical trial design, donor screening, regulatory submissions, clinical and commercial-scale development, and manufacturing.","length":223,"tagName":"p","attribs":{}}]},{"val":[{"type":"...